| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 450 | $70 | $32.2K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 210 | $130 | $26.3K |
| 99309 | The provider sees a patient for a subsequent nursing facility care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or the provider… | 200 | $70 | $13K |
| 99306 | The provider sees a patient for an initial nursing facility care visit involving evaluation and management (E/M). The visit involves high medical decision making, and/or the provider spends at least… | 60 | $130 | $7.7K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 40 | $130 | $5K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 50 | $80 | $3.5K |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 20 | $160 | $2.7K |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 10 | $130 | $1.6K |
| G0008 | Administration of influenza virus vaccine | 50 | $30 | $1.6K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 40 | $40 | $1.6K |